Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2026)
Maxcyte has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $202.5 million for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 15.44% to $202.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $865.7 million through Dec 2025, down 13.21% year-over-year, with the annual reading at $202.5 million for FY2025, 15.44% down from the prior year.
- Liabilities and Shareholders Equity was $202.5 million for Q4 2025 at Maxcyte, down from $213.5 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $291.0 million in Q1 2022 and troughed at $93.1 million in Q2 2021.
- The 5-year median for Liabilities and Shareholders Equity is $266.7 million (2023), against an average of $250.5 million.
- Year-over-year, Liabilities and Shareholders Equity skyrocketed 448.71% in 2021 and then dropped 15.44% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $284.1 million in 2021, then increased by 0.89% to $286.7 million in 2022, then decreased by 6.41% to $268.3 million in 2023, then dropped by 10.74% to $239.5 million in 2024, then decreased by 15.44% to $202.5 million in 2025.
- Per Business Quant, the three most recent readings for MXCT's Liabilities and Shareholders Equity are $202.5 million (Q4 2025), $213.5 million (Q3 2025), and $219.8 million (Q2 2025).